



## Progress in Nanoformulations for Nanomedicine

Guest Editors:

### Prof. Dr. Farid Mena

Departments of Nanomedicine  
and Translational Medicine,  
Fluorotronics-CIC, San Diego, CA  
92037, USA

### Dr. Mohamed Skiba

Associate Professor, UFR  
Medecine-Pharmacie, Pharmacie  
Galénique et de Biopharmacie,  
22 Bd Gambetta, CEDEX, 76183  
Rouen, France

Deadline for manuscript  
submissions:

**closed (15 June 2023)**

### Message from the Guest Editors

Dear Colleagues,

The discovery and characterization of new therapeutic targets and strategies are a permanent process for effective translational medicine and health promotion.

This Special Issue aims at reporting original biochemical compounds (cyclic peptides, peptide hormones, lipopeptides, peptide conjugates, nucleic acid-based drugs), phytoextracts, antibody–drug conjugates, biomarkers of disease, vaccines and their mode of isolation, identification, synthesis and purification followed by their physical-chemical, molecular and pharmacological characterizations.

This SI is open for the publication of studies conducted at the basic science level and preclinical studies. We cordially invite research scholars (e.g., students, pharmacists, industrials, biologists, nanotechnologists, bioengineers, physicians) from all around the world to consider submitting their work, should it be original research, review articles or comprehensive preclinical studies that address the challenges in bringing biological agents or novel targeted theranostic strategies through drug compound identification, development and potential translation from bench to bedside.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)